The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.
The approval process was further expedited by the use of the Assessment Aid, a voluntary submission tool designed to streamline FDA evaluations. Additionally, a priority review voucher was issued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback